Related Experiment Video
Updated: Feb 3, 2026

Real-time Breath Analysis by Using Secondary Nanoelectrospray Ionization Coupled to High Resolution Mass Spectrometry
Published on: March 9, 2018
Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data
Nai-Fang Chi1,2,3, Chi-Pang Wen4, Chung-Hsiang Liu5
11 Department of Neurology School of Medicine College of Medicine Taipei Medical University Taipei Taiwan.
Insights
In real-world practice, clopidogrel showed similar effectiveness to aspirin for preventing recurrent ischemic strokes. However, clopidogrel use was associated with a significantly higher mortality rate compared to aspirin.
Area of Science:
- Cardiology
- Neurology
- Public Health
Background:
- Previous clinical trials suggested clopidogrel's superiority over aspirin for secondary vascular prevention.
- Real-world data is crucial to validate these findings in diverse patient populations.
Purpose of the Study:
- To compare the safety and efficacy of clopidogrel versus aspirin for secondary stroke prevention in a real-world setting.
- To assess stroke recurrence and mortality rates between the two antiplatelet therapies.
Main Methods:
- Retrospective analysis of ischemic stroke patients (2006-2016) from the Taiwan Stroke Registry.
- Comparison of stroke recurrence and mortality between aspirin and clopidogrel groups.
- Propensity score matching and Cox regression to control for confounding factors.
Main Results:
- Stroke recurrence rates were comparable between aspirin and clopidogrel groups after propensity score matching (HR=1.13, P=0.311).
- Mortality rate was significantly higher in the clopidogrel group compared to the aspirin group (HR=1.30, P=0.008).
- Findings remained consistent before and after propensity score adjustment.
Conclusions:
- Clopidogrel is as effective as aspirin in preventing recurrent ischemic stroke in real-world clinical practice.
- Aspirin demonstrated a better safety profile regarding mortality compared to clopidogrel.
Abstract:
Background Clopidogrel was thought to be superior to aspirin for secondary prevention of vascular diseases in clinical trials. In this study we assessed the safety and efficacy of clopidogrel versus aspirin in real-world practice by using the Taiwan Stroke Registry. Methods and Results Patients with ischemic stroke (2006-2016) on aspirin or clopidogrel for secondary stroke prevention were identified in the Taiwan Stroke Registry. Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period. Propensity score matching and conditional Cox proportional hazards regression model were applied to control confounding factors with 6443 patients in each group. After propensity score matching, stroke recurrence rates were comparable between groups, with 223 patients in the aspirin (3.46%) and 244 in the clopidogrel group (3.79%) (hazard ratio=1.13, 95% confidence interval=0.89-1.43, P=0.311). However, the mortality rate was significantly higher in the clopidogrel group (362 patients, 5.62%) than in the aspirin group (302 patients, 4.69%) (hazard ratio=1.30, 95% confidence interval=1.07-1.58, P=0.008). Results were consistent before and after propensity score matching. Conclusions Clopidogrel was as effective as aspirin for prevention of recurrent stroke in real-world practice. However, the mortality rate was significantly higher in the clopidogrel than in the aspirin group.
Related Concept Videos
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Secondary Active Transport
Secondary Active Transport
Secondary Healthcare System
Primary and Secondary Growth in Roots and Shoots
Cancer Prevention
Some...

